Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18). CONCLUSIONS: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationRoentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationRosencher, N., Kerkkamp, H. E. M., Macheras, G., Munuera, L. M., Menichella, G., Barton, D. M., Cremers, S., Abraham, I. L., & Investigation, F. T. O. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00348.x · Cited by 603
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Research works printed but not linked: 1
- 10.1016/s0140-6736(07)61445-7 · DOI · Paper page
Cited by
Items 101–200 of 1,000
Raskob, G. E., Gallus, A. S., Pineo, G. F., Chen, D., Ramirez, L.-M., Wright, R. T., & Lassen, M. R. (2012) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.94b2.27850 · Cited by 112
“South Africa 56 (4) 56 (4) 0 (0) 0 (0) 56 (1) 56 (1) 42 (1) 39 (1)”
Perzborn, E., Heitmeier, S., Laux, V., & Buchmüller, A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.01.017 · Cited by 105
Bleeding and antidotes in new oral anticoagulants
Majeed, A., & Schulman, S. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.001 · Cited by 105
Fuji, T., Fujita, S., Kawai, Y., Nakamura, M., Kimura, T., Fukuzawa, M., Abe, K., & Tachibana, S. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0057-x · Cited by 108
“Japanese patients typically have a lower body weight than patients from the United States or the European Union; notably the mean body weight in this study was 57 kg compared with a mean body weight of 78 kg for patients in the phase 3 trial for rivaroxaban in THA, which included primarily white patients (92 %) [21].”
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations
Harder, S., & Graff, J. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1510-z · Cited by 102
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents
Crowther, M. A., & Warkentin, T. E. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03429.x · Cited by 98
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 105
Heparin concentration is critical for cell culture with human platelet lysate
Hemeda, H., Kalz, J., Walenda, G., Lohmann, M., & Wagner, W. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.05.006 · Cited by 97
Gibson, C. M., Mega, J. L., Burton, P. B. J., Goto, S., Verheugt, F. W. A., Bode, C., Plotnikov, A. N., Sun, X., Cook‐Bruns, N., & Braunwald, E. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.01.026 · Cited by 100
Jensen, C. D., Steval, A., Partington, P. F., Reed, M. R., & Müller, S. (2011) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.93b1.24987 · Cited by 106
Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa
Bauer, K. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04321.x · Cited by 105
Neumann, I., Rada, G., Claro, J. C., Carrasco-Labra, A., Thorlund, K., Akl, E. A., Bates, S. M., & Guyatt, G. H. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00421 · Cited by 94
van Gorp, R. H., & Schurgers, L. J. (2015) · Nutrients · doi:10.3390/nu7115479 · Cited by 103
He, K., Luettgen, J. M., Zhang, D., He, B., Grace, J. E., Xin, B., Pinto, D. J. P., Wong, P. C., Knabb, R. M., Lam, P. Y. S., et al. (2011) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-011-0037-x · Cited by 101
“ment patients, oral fXa inhibitors have demonstrated superior efficacy compared to enoxaparin, whereas oral direct thrombin inhibitors were found to be non-inferior to enoxaparin in these patient populations (Eriksson et al. 2008; Eriksson et al. 2007a, b; Kakkar et al. 2008; Lassen et al. 2008).”
BackgroundPrevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
Lieberman, J. R., & Pensak, M. J. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.01328 · Cited by 102
Old Versus New Oral Anticoagulants: Focus on Pharmacology
Fareed, J., Thethi, I., & Hoppensteadt, D. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134633 · Cited by 97
Recommendations from the ICM-VTE: Hip & Knee
Delegates, T. I.-V. H. &. K. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.21.01529 · Cited by 100
Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation
Esmon, C. T., & Turpie, A. G. G. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0683 · Cited by 95
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 98
Whole blood clots are more resistant to lysis than plasma clots - greater efficacy of rivaroxaban
Varin, R., Mirshahi, S., Mirshahi, P., Klein, C., Jamshedov, J., Chidiac, J., Perzborn, E., Mirshahi, M., Soria, C., & Soria, J. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2012.11.029 · Cited by 94
“Rivaroxaban is approved for several indications, including the prevention of venous thromboembolism in adult patients following elective hip or knee replacement surgery [25–31], treatment of DVT and prevention of recurrent venous thromboembolism (VTE), and prevention of stroke in patients with non-valvular atrial fibr…”
BackgroundJameson, S. S., Rymaszewska, M., James, P., Serrano‐Pedraza, I., Muller, S. D., Hui, A. C. W., & Reed, M. R. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.00521 · Cited by 103
Faour, M., Piuzzi, N. S., Brigati, D. P., Klika, A. K., Mont, M. A., Barsoum, W. K., & Higuera, C. A. (2018) · The Journal of Arthroplasty · doi:10.1016/j.arth.2018.03.001 · Cited by 88
Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
Willmann, S., Becker, C., Burghaus, R., Coboeken, K., Edginton, A. N., Lippert, J., Siegmund, H., Thelen, K., & Mück, W. M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0090-5 · Cited by 89
New oral anticoagulants and regional anaesthesia
Benzon, H. T., Avram, M. J., Green, D., & Bonow, R. O. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet401 · Cited by 93
Grandhi, R., Newman, W. C., Zhang, X., Harrison, G. L., Moran, C. C., Okonkwo, D. O., & Ducruet, A. F. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.08.042 · Cited by 87
Huisman, M. V., Quinlan, D. J., Dahl, O. E., & Schulman, S. (2010) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.957712 · Cited by 90
Self-citationStreiff, M. B., & Haut, E. R. (2009) · JAMA · doi:10.1001/jama.301.10.1063 · Cited by 86
Stewart, D. W., & Freshour, J. E. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r331 · Cited by 90
Haas, S. K., Kreutz, R. H., Mantovani, L. G., Pattanayak, C. W., Holberg, G., Jamal, W., Schmidt, A., van Eickels, M., Lassen, M. R., & Turpie, A. G. G. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-08-0666 · Cited by 86
Self-citationPoultsides, L. A., Valle, A. G. D., Memtsoudis, S. G., Ma, Y., Roberts, T. R., Sharrock, N. E., & Salvati, E. A. (2012) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.94b1.27301 · Cited by 88
Vaglio, S., Prisco, D., Biancofiore, G., Rafanelli, D., Antonioli, P., Lisanti, M., Andreani, L., Basso, L., Velati, C., Grazzini, G., et al. (2016) · PubMed Central · doi:10.2450/2015.0172-15 · Cited by 98
Mak, K. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001592 · Cited by 89
The perioperative management of new direct oral anticoagulants: a question without answers
Castillo, J., Andrés, J. A. D., Gomar, C. G., Gómez‐Luque, A., Hidalgo, F., Llau, J. V., Sierra, P., Torres, L. M., & Ferrandis, R. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-11-0868 · Cited by 85
“Dabigatran 220 mg once daily has been licensed for thromboprophylaxis after THR based on RE-NOVATE (35) and RENOVATE-II (36) as well as after TKR based on RE-MOBILIZE (37) and RE-MODEL (38).”
BackgroundBoyle, K. K., Rachala, S. R., & Nodzo, S. R. (2018) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-018-9498-8 · Cited by 88
Venous thromboembolism following prolonged cast immobilisation for injury to the tendo Achillis
Healy, B., Beasley, R. W., & Weatherall, M. (2010) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.92b5.23241 · Cited by 87
Dahl, O. E., Quinlan, D., Bergqvist, D., & Eikelboom, J. W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03965.x · Cited by 81
Factor Xa and thrombin as targets for new oral anticoagulants
Weitz, J. I. (2010) · Thrombosis Research · doi:10.1016/s0049-3848(10)70147-x · Cited by 86
“undergoing total hip or knee replacement surgery [43–46]”
BackgroundMethodPetersen, P. B., Kehlet, H., Jørgensen, C. C., & on behalf of the Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement Collaborative Group (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675641 · Cited by 85
Roux, P. L., Pollack, C. V., Milan, M., & Schaefer, A. W. (2014) · Journal of neurosurgery · doi:10.3171/2014.8.paradigm · Cited by 83
Kakkos, S., Kirkilesis, G., Caprini, J. A., Geroulakos, G., Nicolaides, A. N., Stansby, G. P., & Reddy, D. J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005258.pub4 · Cited by 79
Polyphenol compounds belonging to flavonoids inhibit activity of coagulation factor X
Bijak, M., Ponczek, M. B., & Nowak, P. (2014) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2014.01.023 · Cited by 82
Lieberman, J. R., & Heckmann, N. D. (2017) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-15-00760 · Cited by 79
A Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty
Colwell, C. W., Froimson, M. I., Anseth, S. D., Giori, N. J., Hamilton, W. G., Barrack, R. L., Buehler, K. C., Mont, M. A., Padgett, D. E., Pulido, P. A., et al. (2014) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.01031 · Cited by 80
Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin
Chan, Y., Yeh, Y., See, L., Wang, C., Chang, S., Lee, H., Wu, L., Tu, H., & Kuo, C.-T. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.063 · Cited by 76
Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
Enriquez, A. A., Lip, G. Y. H., & Baranchuk, A. M. (2015) · EP Europace · doi:10.1093/europace/euv030 · Cited by 81
“6% if the drug is administered at a dose of 10 mg daily for a period of 2–6 weeks.(56,57) In the ROCKET AF study, the annual rates of major bleeding were similar in the rivaroxaban and warfaringroups (3.”
BackgroundNovel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
Steffel, J., & Braunwald, E. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr052 · Cited by 78
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
Siegal, D. M., Lu, G., Leeds, J. M., Karbarz, M. J., Castillo, J., Mathur, V. S., Hutchaleelaha, A., Sinha, U., Kitt, M. M., McClure, M. W., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007112 · Cited by 75
Venker, B. T., Ganti, B. R., Lin, H., Lee, E. D., Nunley, R. M., & Gage, B. F. (2016) · The Journal of Arthroplasty · doi:10.1016/j.arth.2016.09.033 · Cited by 75
Meng, Q., Wang, W., Yu, X., Li, W., Kong, L., Qian, A., Li, C., & Li, X. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25115 · Cited by 72
“Currently, the major preventive agents for DVT are prophylactic anticoagulants, such as low molecular weight heparin (LMWH) and direct Xa inhibitor (rivaroxaban), which could reduce the incidence of venous thromboembolism to 3.7% and 1.1% [Eriksson et al., 2008].”
BackgroundInfluentialWong, P. C., Crain, E. J., WATSON, C. A., & XIN, B. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03503.x · Cited by 74
Cao, Y. B., Zhang, J. D., Shen, H., & Jiang, Y. Y. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0889-z · Cited by 78
“(2008) [11] Multicenter doubleblind RCT Adults, ≥18 years-old who were scheduled to undergo elective total hip arthroplasty Rivaroxaban 10 mg, orally once daily, started 6–8 h after wound closure.”
BackgroundNieto, J. A., Espada, N. G., Merino, R. G., & Cámara, T. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.02.011 · Cited by 79
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban
Fawole, A. A., Daw, H. A., & Crowther, M. A. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.13025 · Cited by 79
Jiang, J., Hu, Y., Zhang, J., Yang, J., Mueck, W., Kubitza, D., Bauer, R., Meng, L., & Hu, P. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0196 · Cited by 73
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Schirmer, S. H., Baumhäkel, M., Neuberger, H., Hohnloser, S. H., Gelder, I. C. V., Lip, G. Y. H., & Böhm, M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.017 · Cited by 76
Venous Thromboembolic Prophylaxis After Total Hip and Knee Arthroplasty
Lieberman, J. R., & Bell, J. A. (2021) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.20.02250 · Cited by 79
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
Willmann, S., Zhang, L., Frede, M., Kubitza, D., Mueck, W., Schmidt, S., Solms, A., Yan, X., & Garmann, D. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12288 · Cited by 73
Feng, W., Wu, K., Liu, Z., Kong, G., Deng, Z., Chen, S., Wu, Y., Chen, M., Liu, S., & Wang, H. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.10.009 · Cited by 72
“The other 8 RCTs evaluated only one dose of direct factor Xa inhibitor [34–41].”
BackgroundLaboratory monitoring of new anticoagulants
Castellone, D. D., & Cott, E. M. V. (2009) · American Journal of Hematology · doi:10.1002/ajh.21607 · Cited by 69
“Peak plasma concentration occurs at 2–4 hrs [12].”
BackgroundCaldeira, D., Barra, M., Ferreira, A., Rocha, A., Augusto, A., Pinto, F. J., Costa, J. N., & Ferreira, J. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13412 · Cited by 73
The 50 Highest Cited Papers in Hip and Knee Arthroplasty
Eom, S. H., & Bamne, A. B. (2014) · The Journal of Arthroplasty · doi:10.1016/j.arth.2014.03.018 · Cited by 68
Kröll, D., Stirnimann, G., Vogt, A. P., Lai, D. L. L., Borbély, Y., Altmeier, J., Schädelin, S., Candinas, D., Alberio, L., & Nett, P. C. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13243 · Cited by 69
Perzborn, E., Heitmeier, S., von Degenfeld, G., Dittrich‐Wengenroth, E., Buchmüller, A., Gerdes, C., Misselwitz, F., & Laux, V. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-02-0134 · Cited by 74
“RECORD 3 also showed a significant reduction in symptomatic VTE, and whereas RECORD1 showed a general trend for reduction in symptomatic VTE, which was not statistically significant.”
MethodSelf-citationThe novel anticoagulants: entering a new era
Bounameaux, H. (2009) · Swiss Medical Weekly · doi:10.4414/smw.2009.12447 · Cited by 76
“RECORD 1 [ 9 ] Total hip arthroplasty Rivaroxaban 10 mg 1.1% (p 9 ] and RECORD 3 [10], rivaroxaban was compared with enoxaparin 40 mg o.d.”
MethodInfluentialDental implant surgery in patients in treatment with the anticoagulant oral rivaroxaban
Moreno, G. G., Aguilar‐Salvatierra, A., Fernández‐Cejas, E., Ruiz, R. A. D., Aleksa, M., & Calvo‐Guirado, J. L. (2015) · Clinical Oral Implants Research · doi:10.1111/clr.12653 · Cited by 99
How Safe Is Thromboprophylaxis in Abdominoplasty?
Dini, G. M., Ferreira, M. C. C., Albuquerque, L. G., & Ferreira, L. M. (2012) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e31826d9fc0 · Cited by 70
Johnston, S. (2016) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.12.010 · Cited by 73
Khorana, A. A., Vadhan‐Raj, S., Kuderer, N. M., Wun, T., Liebman, H. A., Soff, G. A., Belani, C. P., O'Reilly, E. M., McBane, R. D., Eikelboom, J. W., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0171 · Cited by 70
Self-citationGalanis, T., Thomson, L. J., Palladino, M. A., & Merli, G. J. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0559-8 · Cited by 71
“Key points RECORD1 [27] (n = 4541) RECORD2 [29] (n = 2509) RECORD3 [28] (n = 2531) RECORD4 [30] (n = 3148)”
Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty
Fisher, W. (2011) · Canadian Journal of Surgery · doi:10.1503/cjs.007310 · Cited by 68
“The RECORD1 trial showed that the rivaroxaban regimen was significantly more effective than the enoxaparin regimen (40 mg once daily) in reducing total VTE and major VTE (RR reduction 70% and 88%, respect ively) in patients undergoing THA with a treatment duration of 31–39 days.(45) The efficacy and safety of rivaroxa…”
Updated guidelines on outpatient anticoagulation.
Wigle, P. R., Hein, B. E., Bloomfield, H. E., Tubb, M. R., & Doherty, M. (2013) · PubMed · Cited by 63
Becattini, C., Vedovati, M. C., & Agnelli, G. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2011.12.014 · Cited by 69
“In three studies the comparator was enoxaparin given according to the European regimen (40 mg daily starting preoperatively) and in the RECORD 4 study (TKR) enoxaparin was given according to the North American regimen (30 mg twice daily, first dose postoperative) [21–24].”
MethodNew anticoagulants: how to deal with treatment failure and bleeding complications
Kazmi, R. S., & Lwaleed, B. A. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04060.x · Cited by 65
Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™
Casutt, M., Konrad, C. J., & Schuepfer, G. (2012) · Der Anaesthesist · doi:10.1007/s00101-012-2091-4 · Cited by 70
Diamantopoulos, A., Lees, M., Wells, P. S., Forster, F., Ananthapavan, J., & McDonald, H. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-01-0071 · Cited by 64
“The efficacy and safety of rivaroxaban have been demonstrated in four large phase III randomised controlled trials, where rivaroxaban showed a statistically significant improvement over enoxaparin in the primary endpoint of total VTE (16, 19).”
The Prophylaxis of Venous Thromboembolism
Encke, A., Haas, S. K., & Kopp, I. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0532 · Cited by 75
Self-citationEriksson, B. I., Turpie, A. G. G., Lassen, M. R., Prins, M. H., Agnelli, G., Kälebo, P., Wetherill, G., Wilpshaar, J., & Meems, L. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03748.x · Cited by 59
Self-citationEmergency Management of Bleeding Associated With Old and New Oral Anticoagulants
Peacock, W. F., Gearhart, M. M., & Mills, R. M. (2012) · Clinical Cardiology · doi:10.1002/clc.22037 · Cited by 63
Use of anticoagulants in elderly patients
Bauersachs, R. M. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.09.013 · Cited by 67
“The RECORD1 and RECORD3 studies compared rivaroxaban (10 mg od) with enoxaparin 40 mg od, given for 31–39 days after THR (RECORD1) [61], or 10–14 days after TKR (RECORD3) [63].”
Saragas, N. P., Ferrao, P. N. F., Saragas, E., & Jacobson, B. F. (2013) · Foot and Ankle Surgery · doi:10.1016/j.fas.2013.11.002 · Cited by 59
“9% [28–31], - non-major bleeding 2.”
Protocol in managing oral surgical patients taking dabigatran
Breik, O., Cheng, A., Sambrook, P., & Goss, A. N. (2014) · Australian Dental Journal · doi:10.1111/adj.12199 · Cited by 70
Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programme
Haas, S. K. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01230.x · Cited by 62
“In RECORD1 and RECORD3, the drug was significantly more effective than enoxaparin for the prevention of VTE in patients undergoing THR and TKR, respectively.”
BackgroundMethodInfluentialSelf-citationLoke, Y. K., Pradhan, S., Yeong, J. K.-Y., & Kwok, C. S. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12376 · Cited by 63
Old and new anticoagulant drugs: A minireview
Mannucci, P. M., & Franchini, M. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.539250 · Cited by 62
Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population
von Vajna, E., Alam, R., & So, T.-Y. (2016) · Cardiology and Therapy · doi:10.1007/s40119-015-0054-y · Cited by 61
Lieberman, J. R., Cheng, V. C., & Cote, M. P. (2016) · The Journal of Arthroplasty · doi:10.1016/j.arth.2016.09.006 · Cited by 59
Loke, Y. K., & Kwok, C. S. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01162.x · Cited by 56
The top 100 most cited articles on total hip arthroplasty: a bibliometric analysis
Zhang, W., Tang, N., Li, X., George, D. M., He, G., & Huang, T. (2019) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-019-1476-3 · Cited by 56
Xu, X. S., Moore, K. T., Burton, P. B. J., Stuyckens, K., Mueck, W., Rossenu, S., Plotnikov, A. N., Gibson, C. M., & Vermeulen, A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04181.x · Cited by 58
Kakkos, S. K., Warwick, D. J., Nicolaides, A. N., Stansby, G. P., & Tsolakis, I. A. (2012) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.94b6.28128 · Cited by 55
Diretrizes Brasileiras de Antiagregantes Plaquetários e Anticoagulantes em Cardiologia
Filho, A. M. L., Azmus, A., Soeiro, A., Quadros, A., Avezum, Á., Marques, A., Franci, A., Manica, A., Volschan, A., de Paola, A., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s009 · Cited by 95
New antithrombotic agents—insights from clinical trials
Paikin, J. S., Eikelboom, J. W., Cairns, J. A., & Hirsh, J. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.101 · Cited by 58
Burr, N. E., Lummis, K., Sood, R., Kane, J. S., & Subramanian, V. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30162-5 · Cited by 60
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review
Bikdeli, B., Tajrishi, F. Z., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Lippi, G., Siegal, D. M., Eikelboom, J. W., Monréal, M., Jiménez, D., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1292 · Cited by 61
Wang, J. J., Song, Y. J., Pursley, J. M., Wastall, P., Wright, R. N., LaCreta, F. P., Frost, C. E., & Barrett, Y. C. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-09-0634 · Cited by 56
Jameson, S. S., Bottle, A., Malviya, A., Müller, S., & Reed, M. R. (2010) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.92b1.22751 · Cited by 56
The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study
Kröll, D., Nett, P. C., Borbély, Y., Schädelin, S., Calderara, D. B., Alberio, L., & Stirnimann, G. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.08.025 · Cited by 54
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Cohen, A. T., Spiro, T. E., & Spyropoulos, A. C. (2013) · PubMed · doi:10.1056/nejmc1303641 · Cited by 18
Management of refractory anti-phospholipid syndrome
Scoble, T., Wijetilleka, S., & Khamashta, M. A. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.04.030 · Cited by 53
New directions in the diagnosis and treatment of pulmonary embolism in pregnancy
Cutts, B. A., Dasgupta, D., & Hunt, B. J. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.06.035 · Cited by 53
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., & Geerts, W.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Aarhus University Hospital (DK)
- Medical University of South Carolina (US)
- Technical University of Munich (DE)
- Leiden University Medical Center (NL)
- Queen Mary University of London (GB)
- Bayer (Germany) (DE)
- University of Toronto (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-26
- Volume
- 358
- Issue
- 26
- Pages
- 2765-2775
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014491911
- Cited by
- 1,433
- References
- 25
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 24 · 2023: 35 · 2022: 39 · 2021: 55 · 2020: 47 · 2019: 47 · 2018: 60 · 2017: 68 · 2016: 86 · 2015: 92 · 2014: 98 · 2013: 167 · 2012: 159
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, major bleeding, postoperative anticoagulation
- MeSH terms
- Rivaroxaban, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.